Reports & Databases
Subscribe to
our newsletters!
Showing 21–40 of 50 results
- June of 2019This Target Pipeline List provides an overview of P2X3 receptor antagonists in development for treatment of chronic cough, endometriosis and neuropathic pain.€ 50.00
- June of 2019This Target Pipeline List provides an overview of IRAK4 inhibitors in development for treatment of inflammatory diseases and of lymphoma.€ 50.00
- June of 2019This Target Pipeline List provides an overview of FAP-targeted antibodies, fusion proteins and oncolytic viruses in development for treatment of stroma rich tumors.€ 50.00
- June of 2019This Target Pipeline List provides an overview of GPC3-targeted antibody and cell therapeutics in development for treatment of hepatocellular carcinoma (HCC)€ 50.00
- June of 2019This Target Pipeline List provides an overview of DLL3-targeted antibody and cell therapeutics in development for treatment of small cell lung cancer (SCLC).€ 50.00
- June of 2019This report provides you with a landscape description and analysis of T-cell and natural killer (NK) cell engaging bispecific antibodies as of June 2019.€ 2350.00
- May of 2019This report provides an overview of CD33-targeted antibody and cell therapies in development for treatment of acute myeloid leukemia (AML)€ 150.00
- April of 2019This report provides an overview of small molecule inhibitors of Tyk2 in development for treatment of inflammatory diseases.€ 125.00
- April of 2019This report provides an overview of small molecule inhibitors of NLRP3 in development for treatment of chronic inflammatory diseases.€ 75.00
- April of 2019This report provides an overview of therapeutic antibodies against GM-CSF or its receptor in development for treatment of inflammatory diseases.€ 50.00
- March of 2020This report provides an overview of anti-FcRn therapeutic antibodies and proteins in development for treatment of IgG-mediated autoimmune diseases.€ 100.00
- April of 2019This report provides an overview of therapeutic proteins in development for treatment of arginine-dependent tumors or for enzyme replacement therapy.€ 75.00
- April of 2019This report provides an overview of CD40 agonistic antibodies, proteins or viral vectors in development for treatment of solid tumors as monotherapy or in combination therapy.€ 150.00
- March of 2019This report provides a compilation of the global sales data of branded originator recombinant therapeutic proteins and antibodies in the calendar year 2018.€ 80.00
- March of 2019This Target Pipeline List provides an overview of biologic and chemical entities on the market or in development for treatment of hyperuricemia associated with gout or tumor lysis€ 150.00
- February of 2019This report provides an overview of isolated and recombinant asparaginase enzymes on the market or in development for treatment of leukemia and solid tumors.€ 100.00
- May of 2018These reports evaluate the competitive landscape of T-Cell Receptor (TCR)-based therapeutic cells and recombinant antibodies or antibody fusion proteins.
€ 4450.00€ 2670.00 - January of 2019This report informs about the competitive field of novel DNA vaccines in clinical development for prevention and/or treatment of cancer, infectious and other diseases.€ 400.00
